Eris Lifesciences Limited has announced a strategic partnership with Natco Pharma for the commercialisation of semaglutide in India. The announcement was made through a press release dated February 24, 2026.
Semaglutide is a GLP-1 receptor agonist used in the management of Type 2 diabetes and chronic weight management. Under the partnership, Natco Pharma will manufacture generic semaglutide, while Eris will leverage its commercial infrastructure to market the product in India.
Natco Pharma has received approval from the Central Drugs Standard Control Organisation to manufacture generic semaglutide for the Indian market. The launch is expected in March 2026.
The product will target Type 2 diabetes management, aligning with demand in the metabolic care segment. Eris has an established presence in diabetology with engagement across endocrinologists, diabetologists, and physicians.
The addition of semaglutide is intended to strengthen the company’s portfolio in advanced diabetes therapies and expand its presence in GLP-1 based treatments.
Read More: Cipla Shares Decline After US FDA Issues OAI Classification for Partner Facility!
Established in 2007, Eris operates across therapeutic areas including Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. The company manufactures prescription products across 6 facilities and distributes through approximately 5,000 stockists and over 5,00,000 retail pharmacies.
For FY25, Eris reported revenue of approximately ₹2,894 crore. Over the last 3 years, the company has invested around ₹4,000 crore across geographies, technologies, and therapeutic segments.
As of February 24, 2026, at 3:40 PM, Eris Lifesciences share price on NSE was closed at ₹1,384.60 up by 2.36% from the previous closing price.
The partnership between Eris Lifesciences and Natco Pharma enables the commercialisation of semaglutide in India, with regulatory approval secured and launch expected in March 2026. The collaboration combines manufacturing and commercial capabilities within the diabetes and metabolic care segment.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 24, 2026, 4:07 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
